FNY Investment Advisers LLC Takes $132,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

FNY Investment Advisers LLC acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,500 shares of the company's stock, valued at approximately $132,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System boosted its stake in shares of Hims & Hers Health by 3,284.6% in the 4th quarter. New York State Teachers Retirement System now owns 99,812 shares of the company's stock valued at $2,413,000 after purchasing an additional 96,863 shares during the last quarter. Rhumbline Advisers boosted its stake in Hims & Hers Health by 93.8% in the fourth quarter. Rhumbline Advisers now owns 516,224 shares of the company's stock valued at $12,482,000 after acquiring an additional 249,854 shares during the last quarter. Principal Securities Inc. grew its holdings in Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company's stock worth $74,000 after acquiring an additional 1,002 shares during the period. Principal Financial Group Inc. grew its holdings in Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company's stock worth $33,024,000 after acquiring an additional 1,075,355 shares during the period. Finally, Sanctuary Advisors LLC raised its position in shares of Hims & Hers Health by 41.4% during the 4th quarter. Sanctuary Advisors LLC now owns 36,853 shares of the company's stock valued at $891,000 after acquiring an additional 10,796 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 3,236 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the completion of the transaction, the insider now directly owns 170,285 shares in the company, valued at $4,728,814.45. This trade represents a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $58.40, for a total value of $7,482,616.80. Following the transaction, the chief executive officer now directly owns 89,311 shares in the company, valued at $5,215,762.40. This trade represents a 58.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 476,653 shares of company stock worth $20,679,956 over the last ninety days. Insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Up 7.9%

Hims & Hers Health stock opened at $59.86 on Tuesday. The company has a 50 day moving average of $45.77 and a 200-day moving average of $38.46. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The stock has a market capitalization of $13.40 billion, a PE ratio of 136.04 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.05 EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Finally, Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average target price of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.